AHA Coding Clinic® for ICD-9 - 2006 Issue 4; VOLUMES 1 AND 2 NEW/REVISED CODES
Neoplasms of Lymphatic and Hematopoietic Tissues
Effective October 1, 2006, code 238.7, Other lymphatic and hematopoietic tissues, has been expanded to separately identify essential thrombocythemia and various myelodysplastic syndromes. Myeloproliferative disorders and myelodysplastic syndrome are now recognized as hematologic malignancies. For data consistency reasons, the ICD-9-CM will maintain these conditions with the neoplasms of uncertain behavior. Specific codes have been created to enable improved tracking. Essential thrombocythemia is a stem cell disease that leads to an overproduction of platelets (thrombocytes), sometimes with an accompanying increase in white blood cells. If untreated, essential thrombocythemia (ET) can be life threatening. In patients with ET, the blood...
Subscribe or sign in to view the full article.
Article Overview
This article explains an ICD-9-CM update focused on neoplasms of lymphatic and hematopoietic tissues. It covers changes introduced for data tracking, the broad clinical context behind the affected hematologic conditions, and the structure of the revised and newly created diagnosis categories. It is relevant to coders, compliance staff, and other revenue cycle professionals working with hematology and oncology-related diagnosis coding.
Why This Topic Matters
The update affects how certain hematologic conditions are represented in ICD-9-CM and supports more specific reporting and tracking. Readers need this information to understand the scope of the code changes and the related disease groupings discussed in the article.
Article Sections
-
ICD-9-CM update overview
Introduces the effective date and summarizes the scope of the diagnosis coding changes. It also explains the broad purpose of the revision for hematologic conditions.
-
Clinical context: essential thrombocythemia and myelodysplastic syndromes
Provides background on the two major condition groups discussed in the update. The section describes their general clinical characteristics and why they are relevant to hematology coding.
-
Revised and new ICD-9-CM entries
Presents the affected ICD-9-CM categories and the newly created subcategories. It includes additions, deletions, exclusions, and related revisions within the neoplasm classification.
What You Will Learn
- How the ICD-9-CM update is organized around lymphatic and hematopoietic neoplasms.
- Which broad disease groupings are discussed in relation to the revised diagnosis categories.
- What types of structural changes the article describes for the affected diagnosis classifications.
- How the article frames the update for tracking and reporting purposes.
Who Should Read This
- Medical coders
- Coding auditors
- Compliance professionals
- Revenue cycle staff
- Hematology/oncology billing staff
Codes Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com